Project Grant HT94252310771
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This $1,280,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) funds research conducted by The Cleveland Clinic Foundation to investigate how the NF-I/A transcription factor regulates an HIF-independent fatty acid metabolism program in kidney cancer. The award, with a performance period from September 1, 2024 to August 31, 2028, supports the Cleveland Clinic Foundation's research to develop innovative medical solutions for...
The Department of Defense's Defense Health Agency awarded a $1,280,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The grant, awarded on September 1, 2025, supports research investigating the biological mechanisms and therapeutic relevance of the SLC1A1 amino acid transporter in kidney cancer. The Cleveland Clinic Foundation, a renowned nonprofit academic medical center, will conduct this advanced biomedical research...
The Defense Health Agency awarded The Cleveland Clinic Foundation, a non-profit academic medical center, a $893,768 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The two-year grant, effective from September 1, 2023 to August 31, 2025, supports the development of multimodal AI-based solutions to enhance renal cancer patient care. As a leader in medical research, education, and healthcare delivery, The Cleveland Clinic Foundation will leverage its...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
The Defense Health Agency awarded a $176,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, titled "UNRAVELING THE INTERACTIONS OF MITOCHONDRIALLY ENCODED COMPLEX I MUTATIONS WITH HYPOXIA AND ANTITUMOR IMMUNE RESPONSE IN CHROMOPHOBE RENAL CELL CARCINOMA", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans,...
This $168,042 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research on in vivo targeting of TFE3 dimerization partners in translocation renal cell carcinoma (RCC). The grant was awarded to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts, which is a subsidiary of the larger Partners Healthcare System. The research project...
The U.S. Defense Health Agency awarded a $559,992 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation. The grant supports the "Bench-to-Bedside Development of Superior CAR T-Cell Therapy for Leukemia" research project, which aims to transform healthcare for military service members, veterans, and the public through innovative biomedical research. The project will run from September 30, 2025 to September 29, 2028,...
The Defense Health Agency (DHA) awarded a $240,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation to support research on "EXPLORING CAUSALITY AND MECHANISM OF AR ECDNA IN MALIGNANT PROSTATE CANCER PROGRESSION". The grant, with a performance period from March 15, 2025 to March 14, 2027, will fund advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the public....